期刊文献+

胃肠道肿瘤的分子靶向治疗:未来的方向? 被引量:2

The Targeted Therapy of Gastrointestinal Tumor:Is it the Future Direction
下载PDF
导出
摘要 分子靶向治疗是这几年来消化道肿瘤治疗领域的热门话题。这类新一代的分子靶向生物治疗模式,将在临床治疗肿瘤实践中具有广阔的应用前景。从事肿瘤研究的临床医务人员需要综合归纳这些信息,融汇入自己的认知将之合理应用于患者。我们将真正进入传统的细胞毒性药物攻击与非细胞毒性靶向性药物相结合使用的时代,真正实现延长患者的生命,改善其生活质量的目标。 Molecular targeted therapy of the gastrointestinal tumor is a hot topic in the past few years. This new generation of molecularly targeted biological treatment modalities will have broad application prospects in the clinical treatment of cancer practice. Clinical staff who engaged in clinical cancer research need to consolidate these new informations, then rea- sonably apply it to patients. We will truly enter the era of traditional cytotoxic drugs combined with with non--cytotoxic targeted drugs, which really prolong the life of patients and improve the quality of life.
出处 《医学与哲学(B)》 2013年第7期10-12,共3页 Medicine & Philosophy(B)
关键词 分子靶向治疗 胃肠道肿瘤 总生存期 生活质量 molecular targeted therapy, gastrointestinal tumor, overall survival, the quality of life
  • 相关文献

参考文献10

  • 1Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia[J], Blood,2005,105(7) :2640-2653. 被引量:1
  • 2Manley P W,Cowan - Jacob S W, Buchdunger E, et al. Imatinib: aselective tyrosine kinase inhibitor[J]. Eur J Cancer, 2002, 38( Suppl5):S19-S27. 被引量:1
  • 3Van Glabbeke K,Owzar C. Rankin Comparison of two doses of ima-tinib for the treatment of unresectable or metastatic gastrointestinalstromal tumors (GIST) : A meta -analyis based on 1, 640 patients[j]. Journal of Clinical Oncology, 2007,25( 18S) : 10004. 被引量:1
  • 4Hurwitz H ,Fehrenbacher L, Novotny W,et al. Bevacizumabplusiri-notecan, fluorouracil and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004,350(23) :2335~2342. 被引量:1
  • 5Van Cutsem E, Kohne C H, Hitre E, et al. Cetuximab and chemo-therapy as initial treatment for metastatic colorectal cancer[J]. NEngl J Med,2009,360( 14) :1408-1417. 被引量:1
  • 6Bang Y J, Van Cutsem E,Feyereislova A,et al. Trastumab in com-bination with chemotherapy versus chemotherapy alone for treat-ment of Her2 - positive advanced gastric or gastroesophageal junc-tion cancerC ToGA) : a phase 3,open - lable, randomized controlledtrial[J]. Lancet,2010,376(9742) :687-697. 被引量:1
  • 7De Roock W,Claes B’Bernasconi D,et al. Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab pluschemotherapy in chemotherapy-refractory metastaticJ^JJ. LancetOncol,2010,11(8) :753-762. 被引量:1
  • 8Sobrero A F,Manrel J , Fehrenbacher L, et al. EPIC: phase HI trialof cetuximab plus irinotecan after fluoropyrimidine and oxaliplatinfailure in patients with metastasatic colorectal cancer[J]. J Clin On-col,2008,26(14) =2311-2319. 被引量:1
  • 9Maughan T S, Adams R,Smith C G,et al. Oxaliplatin and fluoropy-rimidine chemotherapy plus or minus cetuximab : the effect of infu-sional 5-FU or capecitabine on the outcomes of the MRC COINTrial in advanced colorectal cancer( ACRC) [G]. Meeting: Gastroin-testinal Cancers Symposium,2010,abstr 402. 被引量:1
  • 10Tveit K’Guren T,Glimelius B, et al. Randomized phase HI study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermit-tently with or without cetuximab,as first- line treatment of meta-static colorectal cancer: the NORDICstudy ( NCT00145314) , bythe Nordic Colorectal Cancer Biomodulation Group[J]. J Clin On-col,2011,29(Suppl 4) :abstr 365. 被引量:1

同被引文献31

  • 1马刚,郭克建,张浩,尾崎岩太,松桥幸子,郑新宇,董明.程序性细胞死亡因子4在胰腺癌组织中的表达及临床病理学意义[J].中国医学科学院学报,2005,27(5):597-600. 被引量:11
  • 2Li X,Xin S, Yang D, et al. Down-regulation of PDCIN expression is an independent predictor of poor prognosis in human renal cell carcinoma patients[J]. J Cancer Res Clin Oncol,2012,1:38(3) :529-535. 被引量:1
  • 3Zhen Y,Liu Z,Yang H,et al. Tumor suppressor PDCD4 modulates miR 184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma [J]. Cell Death Dis, 2013,4 : e872. 被引量:1
  • 4Fassan M, Pizzi M, Battaqlia G, et al. Programmed cell death 4 (PD CD4) expression during multistep Barrett's eareinogenesis[J]. J Clin Pathol, 2011,64(3) :274. 被引量:1
  • 5Frankel L B,Christoffersen N R,Jacobsen A,et al. Programmed cell death 4 (Pdcd4) is an important functional target of the microRNA miR21 in breast cancer cellsEJl. J Biol Chem, 2008,283 (2) = 1026- 1033. 被引量:1
  • 6Qiu X, Dong S, Qiao F, et al. HBx-mediated miR-21 upregulation 65represses tumo:suppressor function of PDCD4 in hepatocellular carcinoma[J].Oncogene,2013,32(27) z3296 3305. 被引量:1
  • 7Saxena A,Shoeb M,Ramana K V,et al. Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression[J]. Eur J Cancer, 20 J.3,49(15) :3311-3319. 被引量:1
  • 8Wang Q,Sun Z X, Allgayer H, et al. Downregulation of E cadherin is an essential event in activating.beta-catenin/Tcf dependent tran- scription and expression of its target genes irt Pdcd4 knockdown cells[J]. Oncogene, 2010,29(1) : 128-138. 被引量:1
  • 9Nieves Alicea R, Colburn N H, Simeone A M, et al. Programmed Cell Death 4 inhibits breast cancer ceil invasion by increasing tissue inhibitor of metalloproteinases 2 expression[J]. Breast Cancer Res Treat,2009,114(2) ;203-209. 被引量:1
  • 10Kroczynska B, Sharma B, Eklund E A, et al. Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)- stimulated gene expression and generation of type I IFN responses [J]. Mol Cell Biol,2012,32(14) :2809 2822. 被引量:1

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部